

Bryan S. Walsh, J.D.
Cell Phone: (202) 704-4420
Email: bryan.walsh@hoganlovells.com

AREAS OF INTEREST

Prescription Drug Law and Policy; Health Law

EDUCATION AND TRAINING

The George Washington University Law School, Washington, DC, J.D. with Health Law Concentration, 2020

The George Washington University, Milken Institute School of Public Health, Washington, DC, Health Policy Certificate, 2020

University of North Carolina Wilmington, Wilmington, NC, B.A., *magna cum laude*, Philosophy and Criminology, 2017

BAR ADMISSIONS

District of Columbia Bar (2022)

Massachusetts (2021)

ACADEMIC APPOINTMENTS

Harvard Medical School (2020-2022)

The George Washington University Law School (2026-)

PROFESSIONAL EMPLOYMENT

Current Position

Senior Associate, Hogan Lovells US LLP

Previously Held Positions

Research Fellow, Program on Regulation, Therapeutics, and Law Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School

Legal Intern, Office of the Chief Counsel, United States Food and Drug Administration

Law Clerk, Bread for the City, Domestic Violence Project Legal Clinic
Legal Intern, Domestic Violence Legal Empowerment and Appeals Project (DV
LEAP)

PUBLICATIONS

Articles in Refereed Journals

Bryan S. Walsh et al., *Medicaid Spending on Antiretrovirals From 2007 Through 2019*, *Clinical Infectious Diseases* (2023)

Bryan S. Walsh et al., *Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling*, *Journal of Clinical Oncology* (2022)

Bryan S. Walsh et al., *Recent Orange and Purple Book Legislation Suggests a Need to Bridge Drug and Biologic Regimes*, *Nature Biotechnology* (2022)

Bryan S. Walsh with Doni Bloomfield and Aaron S. Kesselheim, *Patents on Safety Labeling Information: Yet Another Barrier to Generic Drug Competition*, *JAMA Internal Medicine* (2022)

Bryan S. Walsh et al., *Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States*, *JAMA Internal Medicine* (2021)

Bryan S. Walsh et al., *A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs*, *JAMA* (2021)

Bryan S. Walsh & Aaron S. Kesselheim, *CAAP Rule and Prescription Drug Prices*, *Am. Journal of Managed Care* (2021)

Invited Articles

Bryan S. Walsh with Joan Meier, *Uncertain Intent: The Difficulties of Applying a Shared Intent Analysis for Habitual Residence to Infants in Families with Domestic Violence*, *Domestic Violence Report* (2019)

Short Articles/Blog Posts

New Rule Might Increase Out-of-Pocket Drug Costs for Patients, *Bill of Health Blog* (2021)

Skinny Labeling: A Pathway for Timely Generic Drug Competition, *Commonwealth Fund Blog* (2021)

PRESENTATIONS AND PODCASTS

Presentations

Frequency of Generic Drug Approvals with Skinny Labels, AcademyHealth Annual Research Meeting, Poster Presentation; Improving Safety, Quality, and Value (2021)
Why US Companies are Conducting Cell Therapy Clinical Trials Outside the US, World Stem Cell Summit (2023)

Podcasts

Co-pay Accumulator Rule Could Cost Patients at the Pharmacy Counter, Managed Care Cast (2021)

NOTABLE CITATIONS

Brief Amicus Curiae of United States, *Teva Pharmaceuticals, Inc. v. GlaxoSmithKline LLC*, Docket No. 22-37 (2023)

Petition for Writ of Certiorari, *Teva Pharmaceuticals, Inc. v. GlaxoSmithKline LLC*, Docket No. 22-37 (2022)

Brief Amici Curiae of 42 Professors of Law, Economics, Business, and Medicine, *Teva Pharmaceuticals, Inc. v. GlaxoSmithKline LLC*, Docket No. 22-37 (2022)

Brief Amicus Curiae of Association for Accessible Medicines, *Teva Pharmaceuticals, Inc. v. GlaxoSmithKline LLC*, Docket No. 22-37 (2022)

MEDIA

Quoted

'Skinny label' for generic version of a pricey cancer drug cut costs for consumers, Stat News (2022)

'Skinny labels' on generics can save patients money, research shows, but recent court decisions cloud future, Endpoints News (2022)

Growing Controversy Over 'Skinny' Labeling for Generic Drugs — What's at stake in legal battles over patent-avoiding approval pathway for generics, MEDPAGETODAY (2022)

THE GEORGE WASHINGTON UNIVERSITY SERVICE

Kahan Health/FDA Law Fellow

Vice President, Moot Court Board

Executive Articles Editor, The George Washington International Law Review